Dare Bioscience Inc. (NASDAQ:DARE) shares traded unchanged at $1.16 on Wall Street last session.
DARE stock price is now 20.96% away from the 50-day moving average and 5.59% away from the 200-day moving average. The market capitalization of the company currently stands at $96.28M.
A total of 1.96% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in DARE stock. A new stake in Dare Bioscience Inc. shares was purchased by HRT FINANCIAL LP during the first quarter worth $16,000. In total, there are 38 active investors with 9.30% ownership of the company’s stock.
Dare Bioscience Inc. (NASDAQ: DARE) opened at $1.1700 on Tuesday. During the past 12 months, Dare Bioscience Inc. has had a low of $0.82 and a high of $1.88. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 2.20, and a quick ratio of 2.20. The fifty day moving average price for DARE is $0.9590 and a two-hundred day moving average price translates $1.0985 for the stock.
The latest earnings results from Dare Bioscience Inc. (NASDAQ: DARE) was released for Jun, 2022. According to the Biotechnology Company, earnings per share came in at $0, beating analysts’ expectations of -$0.06 by 0.06. This compares to -$0.18 EPS in the same period last year. For the current quarter, analysts expect DARE to generate $1.99M in revenue.
Dare Bioscience Inc.(DARE) Company Profile
Daré Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in the identifying, developing, and marketing products for women’s health in the United States. It develops therapies in the areas of contraception, fertility, and sexual and vaginal health. The company’s product includes XACIATO, a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in female patients 12 years of age and older. Its products in advanced clinical development include Ovaprene, a hormone-free monthly vaginal contraceptive; and Sildenafil Cream, a cream formulation of sildenafil for topical administration to the vulva and vagina for treatment of female sexual arousal disorder. The company’s Phase 1-ready products are DARE-HRT1, a combination of bio-identical estradiol and progesterone intravaginal ring for the treatment of vasomotor symptoms in hormone therapy; DARE-VVA1, a vaginally delivered formulation of tamoxifen to treat vulvar and vaginal atrophy in patients with hormone-receptor positive breast cancer; and DARE-FRT1, an intravaginal ring containing bio-identical progesterone for the prevention of preterm birth and broader luteal phase support as part of an in vitro fertilization treatment plan, as well as DARE-PTB1, an intravaginal ring containing bio-identical progesterone for the prevention of preterm birth. Its products in pre-clinical stage include DARE-LARC1, a combination product designed to provide reversible contraception; ADARE-204 and ADARE-214, an injectable formulations of etonogestrel to provide contraception over 6-month and 12-month periods; and DARE-RH1, a non-hormonal contraception for men and women. The company entered into license agreement with Organon & Co. and Organon International GmbH to commercialize XACIATO. Daré Bioscience, Inc. is headquartered in San Diego, California.